Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice

The analgesic and anti-inflammatory drug sodium salicylate was studied for its potential protective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. C 57BL/6 mice were treated with a single dose of sodium salicylate (50 mg/kg or 100 mg/kg i.p.) or saline immediately before injection of MPTP (30 mg/kg or 40 mg/kg s.c.) or saline. Analysis of striatal dopamine and metabolites as well as immunostaining for tyrosine hydroxylase of nigral sections was performed 7 days after MPTP treatment.MPTP (30 mg/kg) led to a strong decrease in striatal dopamine levels (1.87±0.27 ng/mg) compared to saline-treated controls (15.72±0.78 ng/mg), which was significantly attenuated by sodium salicylate 50 mg/kg and 100 mg/kg (5.59±0.56 ng/mg and 8.64±0.89 ng/mg, respectively). Remarkably, the MPTP-induced loss of tyrosine hydroxylase immunoreactivity in nigral cell bodies was nearly completely prevented by the higher dose of sodium salicylate. Furthermore, salicylate demonstrated radical scavenging effects in an in vitro Fenton system indicated by HPLC determination of the dihydroxylated reaction products of salicylate, namely, 2,3- and 2,5-dihydroxybenzoic acid.The protective effects of salicylate against reversible or irreversible impairments in dopaminergic neurotransmission after MPTP treatment may be related to its radical scavenging properties and other mechanisms which need to be clarified.

[1]  H. Przuntek,et al.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. , 1991, European journal of pharmacology.

[2]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Ingelman-Sundberg,et al.  Hydroxylation of salicylate by microsomal fractions and cytochrome P-450. Lack of production of 2,3-dihydroxybenzoate unless hydroxyl radical formation is permitted. , 1991, The Biochemical journal.

[4]  M. Memo,et al.  Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation , 1996, Science.

[5]  J. Bennett,et al.  Reduction of MPP(+)-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. , 1994, Neuroreport.

[6]  C. Patrono.  Aspirin as an antiplatelet drug. , 1994, The New England journal of medicine.

[7]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[8]  P. Jenner,et al.  Oxidative mechanisms in nigral cell death in Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[9]  J. Bennett,et al.  Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during sytemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions , 1997, Brain Research.

[10]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[11]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[12]  J C Rothwell,et al.  Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.

[13]  C. Spratt,et al.  Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. , 1998, European journal of pharmacology.

[14]  P. Mecocci,et al.  Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[16]  B. Halliwell,et al.  Peroxynitrite-dependent aromatic hydroxylation and nitration of salicylate and phenylalanine. Is hydroxyl radical involved? , 1997, Free radical research.

[17]  K. Tipton,et al.  Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.

[18]  R. Gaynor,et al.  The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β , 1998, Nature.

[19]  Z. Rossetti,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. , 1988, Biochemical pharmacology.

[20]  A. Kupsch,et al.  Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. , 1995, Neuroreport.

[21]  C. Seyfried,et al.  Effects of α‐Phenyl‐tert‐Butylnitrone and Selegiline on Hydroxyl Free Radicals in Rat Striatum Produced by Local Application of Glutamate , 1998, Journal of neurochemistry.

[22]  S. Fahn.  Levodopa-Induced Neurotoxicity , 1997 .

[23]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[24]  S. Przedborski,et al.  Mechanisms of MPTP toxicity. , 1998, Movement disorders : official journal of the Movement Disorder Society.

[25]  P. Barnes,et al.  Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. , 1997, Molecular pharmacology.

[26]  C. Carter,et al.  Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice , 1998, Journal of neurochemistry.

[27]  A. Członkowska,et al.  Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[28]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[29]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[30]  R. Elble.  Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[31]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[32]  R. Floyd,et al.  Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. , 1984, Journal of biochemical and biophysical methods.

[33]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .